Cue Biopharma Shares Outstanding History (CUE)
Cue Biopharma reported 96.6M shares outstanding at the end of fiscal 2025.
View full Cue Biopharma company overviewCue Biopharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 96.6M | 34.8M | +56.30% |
| 2024 | 2024-12-31 | 61.8M | 14.6M | +30.93% |
| 2023 | 2023-12-31 | 47.2M | 0 | 0.00% |
| 2022 | 2022-12-31 | 47.2M | 15.0M | +46.62% |
| 2021 | 2021-12-31 | 32.2M | 1.9M | +6.10% |
| 2020 | 2020-12-31 | 30.4M | 3.8M | +14.27% |
| 2019 | 2019-12-31 | 26.6M | 5.9M | +28.34% |
| 2018 | 2018-12-31 | 20.7M | 1.2M | +6.36% |
| 2017 | 2017-12-31 | 19.5M | — | — |
Cue Biopharma quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.2M | −71.2M | −93.16% |
| Q1 2026 | 2026-03-31 | 3.3M | −58.6M | −94.73% |
| Q4 2025 | 2025-12-31 | 3.2M | −58.6M | −94.79% |
| Q3 2025 | 2025-09-30 | 77.8M | 17.6M | +29.19% |
| Q2 2025 | 2025-06-30 | 76.4M | 27.8M | +57.16% |
| Q1 2025 | 2025-03-31 | 61.8M | 13.2M | +27.09% |
| Q4 2024 | 2024-12-31 | 61.8M | 14.6M | +30.93% |
| Q3 2024 | 2024-09-30 | 60.2M | 15.1M | +33.43% |
| Q2 2024 | 2024-06-30 | 48.6M | 4.9M | +11.20% |
| Q1 2024 | 2024-03-31 | 48.6M | 5.5M | +12.66% |
| Q4 2023 | 2023-12-31 | 47.2M | 4.2M | +9.69% |
| Q3 2023 | 2023-09-30 | 45.1M | 9.7M | +27.52% |
| Q2 2023 | 2023-06-30 | 43.7M | 8.4M | +23.64% |
| Q1 2023 | 2023-03-31 | 43.2M | 9.0M | +26.34% |
| Q4 2022 | 2022-12-31 | 43.0M | 10.8M | +33.66% |
| Q3 2022 | 2022-09-30 | 35.4M | 4.0M | +12.83% |
| Q2 2022 | 2022-06-30 | 35.4M | 3.9M | +12.43% |
| Q1 2022 | 2022-03-31 | 34.2M | 3.7M | +12.05% |
| Q4 2021 | 2021-12-31 | 32.2M | 1.9M | +6.10% |
| Q3 2021 | 2021-09-30 | 31.4M | 1.1M | +3.67% |
| Q2 2021 | 2021-06-30 | 31.5M | 2.2M | +7.40% |
| Q1 2021 | 2021-03-31 | 30.5M | 3.9M | +14.76% |
| Q4 2020 | 2020-12-31 | 30.4M | 3.8M | +14.27% |
| Q3 2020 | 2020-09-30 | 30.3M | 7.3M | +31.70% |
| Q2 2020 | 2020-06-30 | 29.3M | 8.0M | +37.49% |
| Q1 2020 | 2020-03-31 | 26.6M | 5.8M | +27.87% |
| Q4 2019 | 2019-12-31 | 26.6M | 5.9M | +28.34% |
| Q3 2019 | 2019-09-30 | 23.0M | 2.8M | +14.09% |
| Q2 2019 · Jun 30 | 2019-06-30 | 21.3M | 1.2M | +5.88% |
| Q1 2019 · Mar 31 | 2019-03-31 | 20.8M | 652,480 | +3.24% |
| Q4 2018 | 2018-12-31 | 20.7M | 1.2M | +6.36% |
| Q3 2018 | 2018-09-30 | 20.1M | — | — |
| Q2 2018 | 2018-06-30 | 20.1M | — | — |
| Q1 2018 | 2018-03-31 | 20.1M | — | — |
| Q4 2017 | 2017-12-31 | 19.5M | — | — |
Cue Biopharma shares outstanding trends
Over the last five reported fiscal years, Cue Biopharma's shares outstanding moved from 30.4M to 96.6M, a change of 66.3M. The latest reported quarter, Q2 2026, shows 5.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cue Biopharma filings at SEC.gov ↗